How it works, simply
It mimics an appetite-related hormone signal.
What the evidence tells us
Starting a later-stage program does not establish approval or long-term safety.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This guide does not establish a safe dose, interaction profile or long-term safety for self-use. Effects reported for one route or formulation may not apply to another.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates amylin receptors with a long-acting profile.
Sponsor or developer: Zealand Pharma / Roche
Studied or labeled topics: Obesity
2026-09-22: Zealand announced initiation of the Phase 3 ZUPREME program for overweight or obesity.
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- Zealand: Phase 3 ZUPREME initiation announcement ↗ · Sponsor · 2026-09-22
Readability updated October 10, 2026. Evidence review: September 23, 2026 (listed facts only). A wording update is not a new clinical review.